Product
Recombinant Anti-IL-1β Humanized Monoclonal Antibody
Aliases
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 100mg, SSGJ-613 200mg, SSGJ-613 200 mg
3 clinical trials
2 indications
Indication
GoutIndication
Gout ArthritisClinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Open-label, Active-Controlled Phase II Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutStatus: Recruiting, Estimated PCD: 2023-09-01